IMIC(000516) 搜狐财经·2025-05-21 20:34Core Viewpoint - International Medical (000516) is experiencing growth in business scale and revenue, but is still facing losses due to the operational costs of newly established medical projects [1][2]. Group 1: Financial Performance - As of May 21, 2025, International Medical's stock closed at 5.23 yuan, up 0.77%, with a trading volume of 207,800 shares and a turnover of 109 million yuan [1]. - The company's revenue increased from 2.711 billion yuan in 2022 to 4.815 billion yuan in 2024, while the net profit attributable to the parent company improved from a loss of 1.177 billion yuan to a loss of 254 million yuan over the same period [1]. - The number of outpatient and emergency service visits rose from 1.5467 million in 2022 to 2.5727 million in 2024, and the total number of employees increased from 7,750 to 8,858 [1]. Group 2: Stock Buyback and Management Actions - On April 24, 2024, the company announced a stock buyback plan with a total fund of no less than 100 million yuan and no more than 150 million yuan, with a maximum buyback price of 9.16 yuan per share [2]. - As of May 20, 2025, the company had repurchased 19,304,400 shares, accounting for 0.854% of the total share capital, with a total transaction amount of approximately 100 million yuan [3]. - The company’s board and president, Liu Ruixuan, increased their holdings by purchasing 100,000 shares on September 2, 2024 [2].